SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-23-023423
Filing Date
2023-08-14
Accepted
2023-08-14 08:30:18
Documents
14
Period of Report
2023-08-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K atos20230804_8k.htm   iXBRL 8-K 26866
2 EXHIBIT 99.1 ex_554966.htm EX-99.1 101946
  Complete submission text file 0001437749-23-023423.txt   271743

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA atos-20230814.xsd EX-101.SCH 3410
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE atos-20230814_def.xml EX-101.DEF 11425
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE atos-20230814_lab.xml EX-101.LAB 15311
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atos-20230814_pre.xml EX-101.PRE 11585
8 EXTRACTED XBRL INSTANCE DOCUMENT atos20230804_8k_htm.xml XML 2554
Mailing Address 107 SPRING STREET SEATTLE WA 98104
Business Address 107 SPRING STREET SEATTLE WA 98104 206.588.0256
ATOSSA THERAPEUTICS, INC. (Filer) CIK: 0001488039 (see all company filings)

IRS No.: 264753208 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35610 | Film No.: 231166498
SIC: 2834 Pharmaceutical Preparations